FDA Lays Out New Guidance on Cancer Endpoints

Drug Industry Daily
A A
Cancer trials that rely on event-free survival and complete response to treatment as surrogate endpoints will be acceptable to FDA reviewers, the agency says in a new final guidance issued Wednesday.

To View This Article:

Login

Subscribe To Drug Industry Daily